Dana-Farber Cancer Institute

This is your central portal for breaking news, the latest research and important updates from Dana-Farber Cancer Institute. Bookmark this page and check back often for updates.

Meeting News

First-line avelumab, axitinib benefit persists across advanced kidney cancer patient subgroups

February 19, 2019
SAN FRANCISCO — The combination of avelumab and axitinib induced longer PFS and higher objective response rates than sunitinib among previously…
Meeting News

Conservative management becomes most common approach for low-risk prostate cancer

February 12, 2019
Conservative prostate cancer management with active surveillance or watchful waiting increased significantly between 2010 and 2015 among men with…

Harvard professor to receive cancer drug development award

February 9, 2019
Geoffrey Shapiro , MD, PhD, will receive the TAT 2019 Honorary Award for cancer drug development. The award will be presented at TAT…
In the Journals Plus

Black men with low-risk prostate cancer have higher mortality rate

January 25, 2019
Black men diagnosed with low-risk prostate cancer may have more aggressive forms of the disease than nonblack men with the same diagnosis, according…

Dana-Farber Cancer Institute to study link between microbiome, colorectal cancer

January 25, 2019
The Dana-Farber Cancer Institute has received up to $25 million to begin a project that will aim to discover how certain microbes inside a…
Cover Story

Early collaboration with psycho-oncologists can make ‘meaningful difference’ in reducing suicide risk

HemOnc Today, January 25, 2019
Despite treatment advances and corresponding improvements in survival, suicide rates among those with cancer are alarmingly high — two times…
In the Journals Plus

Ibrutinib effective among patients with rare Bing-Neel syndrome

January 18, 2019
Ibrutinib induced rapid and durable responses among patients with Bing-Neel syndrome, a condition that affects only about 1% of patients with…

Dana-Farber Cancer Institute appoints executive vice president

January 13, 2019
James Terwilliger has been appointed executive vice president and chief operating officer at Dana-Farber Cancer Institute. His appointment will be…
In the Journals

3D printing may be used for fit-testing valves before TAVR

December 20, 2018
Researchers developed a novel workflow using 3D printing to help clinicians determine what valve size to use before performing transcatheter aortic…
Meeting NewsPerspective

Surgery choice affects quality of life among younger patients with breast cancer

December 7, 2018
SAN ANTONIO — Local therapy decisions appeared to significantly affect quality of life among young breast cancer survivors, according to study…
Meeting NewsPerspective

Researchers identify gene alterations linked to certain metastatic breast cancers

December 5, 2018
SAN ANTONIO — Ten driver gene alterations appeared more common among a cohort of patients with metastatic hormone receptor-positive…
Meeting NewsPerspective

Shorter chemotherapy course 'equally effective' in diffuse large B-cell lymphoma

December 2, 2018
SAN DIEGO — Reducing administration of CHOP chemotherapy by two cycles appeared as effective as the standard six cycles for younger patients…
Meeting NewsPerspective

Pembrolizumab demonstrates ‘robust’ activity in relapsed, refractory primary mediastinal large B-cell lymphoma

December 2, 2018
SAN DIEGO — Pembrolizumab demonstrated considerable antitumor activity among patients with relapsed or refractory primary mediastinal large…
Meeting NewsPerspective

Autologous gene therapy shows promise for sickle cell disease

December 2, 2018
SAN DIEGO — An adult with sickle cell disease responded positively to autologous gene therapy, providing the first proof that this approach…
Meeting NewsPerspective

Ibrutinib alone, with rituximab improves PFS in chronic lymphocytic leukemia

December 1, 2018
SAN DIEGO — The use of ibrutinib alone or with rituximab prolonged PFS compared with bendamustine plus rituximab among previously untreated…
Meeting NewsPerspective

Luspatercept effectively treats anemia in transfusion-dependent myelodysplastic syndrome

December 1, 2018
SAN DIEGO — Luspatercept significantly reduced the transfusion burden compared with placebo among patients with anemia due to myelodysplastic…

Trove of brain cancer data available for study through Georgetown platform

November 27, 2018
One of the largest collections of brain cancer biomedical data in the United States is now available for study through the open access Georgetown…
Cover Story

Advances in myeloma treatments, diagnostics have specialists ‘talking about cure’

HemOnc Today, November 25, 2018
A decade ago, patients with newly diagnosed multiple myeloma typically survived 3 to 5 years. However, the development of highly effective therapies…
Meeting News

Sarcoma treatments evolve as understanding of disease biology improves

November 7, 2018
NEW YORK — The treatment landscape in sarcoma is evolving rapidly as the research community recognizes the importance of matching therapies to…

ESMO honors several oncology leaders

October 31, 2018
European Society for Medical Oncology honored several oncology leaders during its annual congress. Jean-Charles Soria, MD, PhD, received the…